Repligen reported $43.84M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Agilent USD 577M 77M Jun/2026
Align Technology USD 232.86M 3.72M Jun/2026
Bio Techne USD 115.94M 763K Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Bruker USD 143.2M 33.2M Jun/2026
Charles River Laboratories USD 298.04M 25.1M Sep/2026
Danaher USD 2.1B 257M Sep/2026
Dentsply International USD 146M 44M Sep/2026
General Electric Aerospace USD 3.32B 265M Sep/2026
Henry Schein USD 321M 33M Sep/2026
Illumina USD 330M 80M Jun/2026
IQVIA Holdings USD 1.03B 38M Sep/2026
Mettler Toledo International USD 366.1M 43.45M Sep/2026
Myriad Genetics USD 14.3M 4M Dec/2025
OraSure Technologies USD -17.7M 4.06M Dec/2025
Pacific Biosciences Of California USD -35.4M 5.78M Sep/2025
Pfizer USD 6.36B 350M Sep/2026
Repligen USD 43.84M 70K Sep/2026
Revvity USD 227.55M 629K Sep/2026
Standard Biotools USD -6.56M 1.45M Jun/2026
Thermo Fisher Scientific USD 3.79B 244M Sep/2026
Waters USD 554M 158M Sep/2026
West Pharmaceutical Services USD 267.4M 23.8M Sep/2026